Status:

COMPLETED

Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization

Lead Sponsor:

University of Bern

Collaborating Sponsors:

University of Zurich

Conditions:

Coronary Heart Disease

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

Context: Sirolimus-eluting stents and paclitaxel-eluting stents, as compared with bare-metal stents, reduce the risk of restenosis. It is unclear whether there are differences in safety and efficacy b...

Detailed Description

Design: Randomized controlled, observer-blind trial comparing sirolimus-eluting stents with paclitaxel-eluting stents Patients: 1012 patients undergoing percutaneous coronary intervention. The two gr...

Eligibility Criteria

Inclusion

  • Patients with either stable angina or an acute coronary syndrome were eligible to participate if they had at least one lesion with stenosis of at least 50 percent in a vessel with a reference diameter between 2.25 and 4.00 mm that was suitable for stent implantation.

Exclusion

  • Allergy to antiplatelet drugs, heparin, stainless steel, contrast agents, sirolimus, or paclitaxel; participation in another coronary-device study; and terminal illness.

Key Trial Info

Start Date :

April 1 2003

Trial Type :

INTERVENTIONAL

End Date :

Estimated Enrollment :

1012 Patients enrolled

Trial Details

Trial ID

NCT00297661

Start Date

April 1 2003

Last Update

October 20 2006

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University Hospital Bern

Bern, Switzerland, 3010

Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization | DecenTrialz